Western literature

Clarivate Measures Research Performance of the World's Leading Economies in Annual G20 Scorecard Report

Retrieved on: 
Tuesday, October 19, 2021
Interview, Policy, Web of Science, China, Economics, Institute, Western literature, COVID-19, NYSE, Social, Research, Intellectual property, International, Invention, United Kingdom, Female, Workforce, Annual report, Health, Institute for Scientific Information, Clarivate, Engineering, GDP, GERD, Solution, Pharmaceutical industry, Renewable energy, Agriculture, Healthcare, Drug, Dietary supplement

LONDON, Oct. 19, 2021 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today launched a new report which examines the research performance of each of the member countries of the G20 with a visual comparative snapshot for each nation. It also includes a special analysis of the G20 members' COVID-19 research as indexed in the Web of Science™ research publication and citation index.

Key Points: 
  • It also includes a special analysis of the G20 members' COVID-19 research as indexed in the Web of Science research publication and citation index.
  • The report, The Annual G20 Scorecard Research Performance 2021 has been created by the Institute for Scientific Information at Clarivate ahead of this year's G20 Summit, which will be hosted virtually by Rome, Italy on October 30-31.
  • The report focuses on the different national responses to COVID-19 and the link to each region's research investment and subject diversity.
  • Key factors that contribute to impactful research are laid out for each nation in the report and benchmarked.

Clarivate Measures Research Performance of the World's Leading Economies in Annual G20 Scorecard Report

Retrieved on: 
Tuesday, October 19, 2021
Interview, Policy, Web of Science, China, Economics, Institute, Western literature, COVID-19, NYSE, Social, Research, Intellectual property, International, Invention, United Kingdom, Female, Workforce, Annual report, Health, Institute for Scientific Information, Clarivate, Engineering, GDP, GERD, Solution, Pharmaceutical industry, Renewable energy, Agriculture, Healthcare, Drug, Dietary supplement

LONDON, Oct. 19, 2021 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today launched a new report which examines the research performance of each of the member countries of the G20 with a visual comparative snapshot for each nation. It also includes a special analysis of the G20 members' COVID-19 research as indexed in the Web of Science™ research publication and citation index.

Key Points: 
  • It also includes a special analysis of the G20 members' COVID-19 research as indexed in the Web of Science research publication and citation index.
  • The report, The Annual G20 Scorecard Research Performance 2021 has been created by the Institute for Scientific Information at Clarivate ahead of this year's G20 Summit, which will be hosted virtually by Rome, Italy on October 30-31.
  • The report focuses on the different national responses to COVID-19 and the link to each region's research investment and subject diversity.
  • Key factors that contribute to impactful research are laid out for each nation in the report and benchmarked.

Clarivate Demonstrates 2021 Nobel Prediction Success in Every Field of Science and Economics

Retrieved on: 
Wednesday, October 13, 2021
Intellectual property, Collection, Paganini Competition, Income, Nobel Prize, Method, Physics, Attention, Nobel Prize in Chemistry, List of Nobel laureates, Citation, Temperature, Committee for the Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel, Economics, Nobel Memorial Prize in Economic Sciences, Clarivate, Unemployment, Terrorism, Nobel, Education, Nobel Prize in Physics, Clarivate Citation Laureates, University, Mark (given name), Invention, Institute, Physiology, Web of Science, Association, Western literature, Hall, Nobel Assembly at the Karolinska Institute, NYSE, Solution, Laureate, Nobel Prize in Physiology or Medicine, Research, Pharmaceutical industry, Palladium

LONDON, Oct. 13, 2021 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today celebrates the five new Nobel Laureates across the fields of science and economics who were accurately identified as potential Nobel Prize recipients. Each individual was awarded the designation of Citation Laureate™ as much as 12 years prior to being named by the Nobel Assembly. Clarivate is the only organization in the world to use quantitative data together with expert qualitative analysis to identify the pinnacle realm of scientific contributions recorded in the Web of Science.™ Using this approach, Clarivate identifies researchers 'of Nobel class' and forecasts those who could be awarded the Nobel Prize.

Key Points: 
  • Using this approach, Clarivate identifies researchers 'of Nobel class' and forecasts those who could be awarded the Nobel Prize.
  • The five Citation Laureates named as Nobel Laureates in 2021 are:
    The 2021 Nobel Prize for Physiology or Medicine, awarded to David Julius and Ardem Patapoutian, for their discoveries of receptors for temperature and touch.
  • He is our 60th Nobel awardee and the 16th individual who has gone on to receive a Nobel in the field of Physiology or Medicine.
  • Giorgio Parisi was identified as a potential Nobel honoree by Clarivate just a few weeks ago, in September 2021.

Clarivate Demonstrates 2021 Nobel Prediction Success in Every Field of Science and Economics

Retrieved on: 
Wednesday, October 13, 2021
Intellectual property, Collection, Paganini Competition, Income, Nobel Prize, Method, Physics, Attention, Nobel Prize in Chemistry, List of Nobel laureates, Citation, Temperature, Committee for the Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel, Economics, Nobel Memorial Prize in Economic Sciences, Clarivate, Unemployment, Terrorism, Nobel, Education, Nobel Prize in Physics, Clarivate Citation Laureates, University, Mark (given name), Invention, Institute, Physiology, Web of Science, Association, Western literature, Hall, Nobel Assembly at the Karolinska Institute, NYSE, Solution, Laureate, Nobel Prize in Physiology or Medicine, Research, Pharmaceutical industry, Palladium

LONDON, Oct. 13, 2021 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today celebrates the five new Nobel Laureates across the fields of science and economics who were accurately identified as potential Nobel Prize recipients. Each individual was awarded the designation of Citation Laureate™ as much as 12 years prior to being named by the Nobel Assembly. Clarivate is the only organization in the world to use quantitative data together with expert qualitative analysis to identify the pinnacle realm of scientific contributions recorded in the Web of Science.™ Using this approach, Clarivate identifies researchers 'of Nobel class' and forecasts those who could be awarded the Nobel Prize.

Key Points: 
  • Using this approach, Clarivate identifies researchers 'of Nobel class' and forecasts those who could be awarded the Nobel Prize.
  • The five Citation Laureates named as Nobel Laureates in 2021 are:
    The 2021 Nobel Prize for Physiology or Medicine, awarded to David Julius and Ardem Patapoutian, for their discoveries of receptors for temperature and touch.
  • He is our 60th Nobel awardee and the 16th individual who has gone on to receive a Nobel in the field of Physiology or Medicine.
  • Giorgio Parisi was identified as a potential Nobel honoree by Clarivate just a few weeks ago, in September 2021.

Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924’s Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity

Retrieved on: 
Thursday, October 7, 2021
MDM2, Therapy, Poster, Conference, Pemetrexed, GLOBE, Cancer, Bone marrow, Apoptosis, GI, U.S. Securities and Exchange Commission, MDMX, Radiation, Serum, Human, Private Securities Litigation Reform Act, Immunotherapy, Mouse, Security (finance), AACR, Western literature, Annual report, Aileron, ADP, Coronavirus, ALRN, Patient, Research, Risk, Nasdaq, Biomarker, Tissue, Pharmaceutical industry, Medical imaging

BOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today presented new preclinical data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021 on ALRN-6924, currently in development as a novel, selective chemoprotective agent. The new data demonstrated ALRN-6924’s activity as a radioprotective agent in preclinical mouse models of acute radiation-induced toxicity, leveraging the same mechanism of action – p53 activation and subsequent p21 upregulation as well as p21-induced cell cycle arrest – that has clinically shown protection against chemotherapy-induced toxicities.

Key Points: 
  • The new data demonstrated ALRN-6924s activity as a radioprotective agent in preclinical mouse models of acute radiation-induced toxicity, leveraging the same mechanism of action p53 activation and subsequent p21 upregulation as well as p21-induced cell cycle arrest that has clinically shown protection against chemotherapy-induced toxicities.
  • Dr. Aivado continued, Developing ALRN-6924 as a selective chemoprotective agent in p53-mutated cancers continues to be our chief priority.
  • Aileron is currently conducting a Phase 1b randomized, double-blind, placebo-controlled study of ARLN-6924 as a chemoprotective agent in the United States and Europe.
  • Aileron is a clinical stage chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients.

Immunotherapeutic Benefits of the DPX Delivery Platform Featured in Two Poster Presentations at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Thursday, October 7, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, NASDAQ, Twitter, Company, Forward-looking statement, IMV, University of Toronto Faculty of Medicine, Technology, Ovarian cancer, EDGAR, Breast, Conference, Survivin, Department, DPX, Merck, Cancer, LinkedIn, SEDAR, Terminology, Mission statement, TSX, 2021 Essex County Council election, Immune system, Immunotherapy, AACR, Western literature, Bladder cancer, Faculty, Patient, Poster, DLBCL, Pharmaceutical industry, Vaccine

More specifically, the first presentation provides compelling evidence that the DPX technology triggers a more consistent and persistent immune response than conventional emulsions.

Key Points: 
  • More specifically, the first presentation provides compelling evidence that the DPX technology triggers a more consistent and persistent immune response than conventional emulsions.
  • I believe that patients with bladder cancer will benefit from this treatment while maintaining their quality of life.
  • Survivin peptides formulated in the DPX delivery platform rather than standard emulsions, elicit a robust, sustained T cell response to survivin in advanced and recurrent ovarian cancer patients.
  • IMV is pioneering a novel class of cancer immunotherapies based on the Companys proprietary delivery platform (DPX).

Dyne Therapeutics Presents New In Vivo Data for its Duchenne Muscular Dystrophy Program During Muscle Study Group Annual Scientific Meeting Demonstrating Robust and Durable Exon Skipping and Dystrophin Expression

Retrieved on: 
Friday, October 1, 2021
Mortality, Therapy, DM1, Duchenne muscular dystrophy, Security (finance), Form 10-Q, Muscle, Private Securities Litigation Reform Act, GLP, U.S. Securities and Exchange Commission, FRCPCH, Patient, PMO, LinkedIn, Western literature, Transferrin, Heart, Toxicology, GLOBE, Twitter, Dystrophin, Myopathy, Program, Terminology, Disease, DMD, Clinic, DYN, Exon, COVID-19, Degenerative disease, Duchenne, University College London, Dyne, Data, Facioscapulohumeral muscular dystrophy, FSHD, Nasdaq, Cardiac muscle, Time, Mutation, SEC, FORCE, Diaphragm, Dietary supplement, Dentistry, Vaccine, Aluminium, Pharmaceutical industry

WALTHAM, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, announced new data being presented today during the 2021 Muscle Study Group Annual Scientific Meeting for its Duchenne muscular dystrophy (DMD) program that demonstrate robust and durable exon skipping and dystrophin expression in both cardiac and skeletal muscles in in vivo models.

Key Points: 
  • The magnitude of dystrophin expression and percent dystrophin-positive fibers achieved in these mdx mice studies, a widely accepted preclinical model for Duchenne muscular dystrophy, are very compelling.
  • Dynes FORCE platform targets the transferrin 1 (TfR1) receptor, which is highly expressed on the surface of muscle cells.
  • DYNE-251, the lead program in Dynes DMD franchise, is being developed for patients with mutations amenable to skipping exon 51.
  • Dyne links therapeutic payloads to its TfR1-binding fragment antibody (Fab) to develop targeted therapeutics for muscle diseases.

Celyad Oncology to Present New Data on Allogeneic CAR T Therapy Program at the Society for Immunotherapy of Cancer Annual Meeting

Retrieved on: 
Friday, October 1, 2021
U.S. Securities and Exchange Commission, Clinical trial, Time, 2021 Essex County Council election, RNA, Mont-Saint-Guibert, Annual report, Society for Immunotherapy of Cancer, Euronext, Private Securities Litigation Reform Act, Cancer, Patient, Annual general meeting, Western literature, Lymphatic system, Wallonia, Company, Immunotherapy, Intrinsic termination, Date, Risk, FOLFOX, COVID-19, Technology, Uncertainty, CAR, Forward-looking statement, Safety, Pembrolizumab, SITC, SEC, Society, GLOBE, Pharmaceutical industry, Animal

Following the presentation at the meeting, the posters will be available in the Scientific Publications section of Celyad Oncologys website.

Key Points: 
  • Following the presentation at the meeting, the posters will be available in the Scientific Publications section of Celyad Oncologys website.
  • ET, November 12, 2021
    Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.
  • Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY.
  • The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs.

Potential Response Predictors to IMV’s Lead Compound in the DeCidE Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting

Retrieved on: 
Friday, October 1, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, IMV, DPX, Breast, Bladder cancer, Poster, Mission statement, LinkedIn, Western literature, Immunotherapy, Twitter, Merck, Company, Terminology, SEDAR, EST, Forward-looking statement, Survivin, EDGAR

IMV is pioneering a novel class of cancer immunotherapies based on the Companys proprietary delivery platform (DPX).

Key Points: 
  • IMV is pioneering a novel class of cancer immunotherapies based on the Companys proprietary delivery platform (DPX).
  • This patented technology leverages a differentiated mechanism of action that generates a targeted and durable immune activation with limited side effects.
  • IMVs lead candidate, maveropepimut-S (formerly named DPX-Survivac), is a T cell-activating immunotherapy that combines the utility of the platform with a novel cancer target: survivin.
  • IMV is currently assessing maveropepimut-S in breast and advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck.

IMV’s DPX Delivery Technology to be Showcased in Two e-Posters at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Thursday, September 30, 2021
Research, Public Policy, Government, Healthcare Reform, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, IMV, DPX, Breast, Bladder cancer, Poster, Mission statement, LinkedIn, Western literature, Immunotherapy, Twitter, Merck, Company, Terminology, SEDAR, Forward-looking statement, Survivin, EDGAR

IMV is pioneering a novel class of cancer immunotherapies based on the Companys proprietary delivery platform (DPX).

Key Points: 
  • IMV is pioneering a novel class of cancer immunotherapies based on the Companys proprietary delivery platform (DPX).
  • This patented technology leverages a differentiated mechanism of action that generates a targeted and durable immune activation with limited side effects.
  • IMVs lead candidate, maveropepimut-S (formerly named DPX-Survivac), is a T cell-activating immunotherapy that combines the utility of the platform with a novel cancer target: survivin.
  • IMV is currently assessing maveropepimut-S in breast and advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck.